CN-680000-ME216-A4.pdf

AHCA CONTRACT NO. MED216

AMENDMENT NO.4

AHCA Contract No. MED216, Amendment No. 4, Page 1 of 3

THIS CONTRACT, entered into between the STATE OF FLORIDA, AGENCY FOR HEALTH CARE ADMINISTRATION, hereinafter referred to as the "Agency" and FLORIDA MEDICAL SCHOOLS QUALITY NETWORK, INC., hereinafter referred to as the "Vendor," is hereby amended as follows:

1. Standard Contract, Section II., THE AGENCY AGREES, Sub-Section A., Contract Amount, the first sentence is hereby amended to now read as follows:

To pay for contracted services according to the conditions of Attachment I., Scope of Services, in an amount not to exceed $847,965.00, (an increase of $250,000.00), subject to the availability of funds.

2. Attachment I, Scope of Services, Section II., Manner of Service(s) Provision, Sub- Section B., Services Provided by the Vendor, Item 1., Projects to be Completed by the Vendor, is hereby amended to include Sub-Item c., Project 3: Biennial Sickle Cell Disease Report, as follows:

c. Project 3: Biennial Sickle Cell Disease Study Report

The purpose of this project is to conduct a study and produce a report on Medicaid recipients with sickle cell disease as described in Section 409.9125, Florida Statutes. Beginning November 1, 2024, and by November 1 every other year thereafter, the Agency shall submit a report of its findings and recommendations from the preceding 2-year review to the Governor, the President of the Senate, the Speaker of the House of Representatives, the Office of Minority Health and Health Equity, and the Rare Disease Advisory Council. The Agency shall also publish the report on its website in a manner that is easily accessible by the public.

The Vendor shall conduct the following activities, at a minimum, in meeting the requirements of this Contract:

1) Conduct a review to determine whether the available covered medications, treatments, and services for sickle cell disease are adequate to meet the needs of Medicaid recipients diagnosed with such disease and whether the agency should seek to add additional medications, treatments, or services to improve outcomes.

2) Identify the total number of Medicaid recipients diagnosed with sickle cell disease.

3) Identify the number of recipients who experienced two or more emergency room visits or two or more hospital inpatient admissions in a 12-month period, including the length of stay and the total related expenditures, both medical and pharmaceutical, for those recipients.

4) For both populations, provide the following detailed information:

i. Age and population demographics characteristics

ii. Health care utilization patterns

DocuSign Envelope ID: 74365CBA-125F-4341-8681-486861B1C254DocuSign Envelope ID: 28B79FAF-8443-4D94-8A6D-88A66FE263AB http://www.leg.state.fl.us/statutes/index.cfm?App_mode=Display_Statute&Search_String=&URL=0400-0499/0409/Sections/0409.91235.html http://www.leg.state.fl.us/statutes/index.cfm?App_mode=Display_Statute&Search_String=&URL=0400-0499/0409/Sections/0409.91235.html

AHCA Contract No. MED216, Amendment No. 4, Page 2 of 3

iii. Total expenditures for both pharmaceutical and medical services provided by the Medicaid program.

iv. Number of clinical treatment programs available that are contracted with managed care plans, per region, for the care of the Florida Medicaid recipients that are specifically designed or certified to provide health care coordination and health care access for individuals with SCD.

5) Conduct an assessment of the Agency’s existing payment methodologies for approved treatment or drug products for the treatment of sickle cell disease in the inpatient setting and whether such payment methodologies result in barriers to access to care.

6) If barriers to access are identified, an assessment of whether such methodologies may be modified or improved through the adoption of revised or new policies.

7) Consult with a dedicated sickle cell disease medical treatment and research center which maintains a sickle cell patient database and tracks sickle cell disease outcome measures.

3. Attachment I, Scope of Services, Section XIV., Definitions and Acronyms, Sub-Section

B., Acronyms, is hereby amended to add:

APA American Psychological Association

4. Attachment I, Scope of Services, Exhibit A, Deliverables and Financial Consequences, is hereby deleted in its entirety and replaced with Exhibit A-1, Revised Deliverables, Financial Consequences and Performance Standards, attached hereto and made a part of this Contract. All references in this contract to Exhibit A, shall hereinafter refer to Exhibit A-1.

All provisions not in conflict with this Amendment are still in effect and are to be performed at the level specified in this Contract.

This Amendment and all its attachments are hereby made a part of this Contract.

This Amendment cannot be executed unless all previous Amendments to this Contract have been fully executed.

REMAINDER OF PAGE INTENTIONALLY LEFT BLANK

DocuSign Envelope ID: 74365CBA-125F-4341-8681-486861B1C254DocuSign Envelope ID: 28B79FAF-8443-4D94-8A6D-88A66FE263AB

AHCA Contract No. MED216, Amendment No. 4, Page 3 of 3

IN WITNESS WHEREOF, the Parties hereto have caused this fifteen (15) page Amendment to be executed by their officials thereunto duly authorized. This Amendment is not valid until signed and dated by both Parties.

FLORIDA MEDICAL SCHOOLS QUALITY

NETWORK, INC.

STATE OF FLORIDA, AGENCY FOR

HEALTH CARE ADMINISTRATION

SIGNED

BY:

SIGNED

BY:

NAME: NAME:

TITLE: TITLE:

DATE: DATE:

List of Attachments included as part of this Amendment:

Specify Type Number Description Attachment I Exhibit A-1 Revised Deliverable, Financial

Consequences and Performance Standards (12 pages)

REMAINDER OF PAGE INTENTIONALLY LEFT BLANK

DocuSign Envelope ID: 74365CBA-125F-4341-8681-486861B1C254

Dr. Charles Lockwood

12/20/2023 | 11:27 EST

EVP USF Health, Dean, Morsani College of Medicine

DocuSign Envelope ID: 28B79FAF-8443-4D94-8A6D-88A66FE263AB

Deputy Secretary

Austin Noll

ATTACHMENT I

EXHIBIT A-1

REVISED DELIVERABLES, FINANCIAL CONSEQUENCES AND PERFORMANCE

STANDARDS

AHCA Contract No. MED216, Exhibit A-1, Page 1 of 12

1.

DELIVERABLE 1

D01: Donor Milk Bank Timeline

SUPPORTING DOCUMENTATION

The Vendor shall submit a timeline that provides a description of the activities and due dates that shall be completed for the Study on the Use of Donor Human Milk as a supplement to newborn care for infants born prematurely and hospitalized within the NICU in accordance with Attachment I, Scope of Services, Section II., Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1.a.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

July 30, 2021, or within five (5) days of execution of this Contract, whichever is sooner

(COMPLETED)

AMOUNT

N/A

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with Attachment I, Scope of Services, Section II., Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1.a.

2.

DELIVERABLE 2

D02: Donor Human Milk Banks

SUPPORTING DOCUMENTATION

The Vendor shall submit a list of donor human milk banks and companies supplying donor-derived human milk to infants in Florida in accordance with Attachment I, Scope of Services, Section II., Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1.a.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

September 1, 2021 (COMPLETED)

AMOUNT

N/A

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with Attachment I, Scope of Services, Section II., Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1.a.

DocuSign Envelope ID: 74365CBA-125F-4341-8681-486861B1C254DocuSign Envelope ID: 28B79FAF-8443-4D94-8A6D-88A66FE263AB

REVISED DELIVERABLES, FINANCIAL CONSEQUENCES AND PERFORMANCE

STANDARDS

AHCA Contract No. MED216, Exhibit A-1, Page 2 of 12

3.

DELIVERABLE 3

D03: Donor Human Milk Safety

SUPPORTING DOCUMENTATION

The Vendor shall submit an itemized list and description of the safety considerations in utilizing human milk for newborns in the NICU and the adulterants and contaminants that can be transmitted via human milk in accordance with Attachment I, Scope of Services, Section II., Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1.a.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

September 17, 2021 (COMPLETED)

AMOUNT

$115,988.33

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with Attachment I, Scope of Services, Section II., Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1.a.

FINANCIAL CONSEQUENCES

Failure to complete and submit Deliverable 3 in the time and manner specified in accordance with this Contract will result in a payment reduction equal to ten percent (10%) of the total invoiced amount.

4.

DELIVERABLE 4

D04: Donor Human Milk Data

SUPPORTING DOCUMENTATION

The Vendor shall submit data showing the use by Florida hospitals of donor human milk made available via donor human milk banks and the related health outcomes and achieved cost-savings for both Medicaid and commercial payors regarding newborn care within a NICU in accordance with Attachment I, Scope of Services, Section II., Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1.a.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

September 24, 2021 (COMPLETED)

AMOUNT

$115,988.33

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with Attachment I, Scope of Services, Section II., Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1.a.

DocuSign Envelope ID: 74365CBA-125F-4341-8681-486861B1C254DocuSign Envelope ID: 28B79FAF-8443-4D94-8A6D-88A66FE263AB

REVISED DELIVERABLES, FINANCIAL CONSEQUENCES AND PERFORMANCE

STANDARDS

AHCA Contract No. MED216, Exhibit A-1, Page 3 of 12

FINANCIAL CONSEQUENCES

Failure to complete and submit Deliverable 4 in the time and manner specified in accordance with this Contract will result in a payment reduction equal to ten percent (10%) of the total invoiced amount.

5.

DELIVERABLE 5

D05: Donor Human Milk Data Recommendations

SUPPORTING DOCUMENTATION

The Vendor shall submit recommendations of best practices which must address, at a minimum: the operation of a donor human milk tissue bank that facilitates the donation, processing and distribution of donor human milk tissue and donor human milk tissue derivatives; procedures for donation and distribution of donor human milk tissue and donor human milk tissue derivatives; and testing of donor human milk tissue and donor human milk tissue derivatives before donation, processing, and distribution to ensure the absence of adulterants and other contaminants, in accordance with Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B. Services Provided by the Vendor, Item 1.a.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

September 24, 2021 (COMPLETED)

AMOUNT

$115,988.34

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with Attachment I, Scope of Services, Section II., Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1.a.

FINANCIAL CONSEQUENCES

Failure to complete and submit Deliverable 5 in the time and manner specified in accordance with this Contract will result in a payment reduction equal to ten percent (10%) of the total invoiced amount.

6.

DELIVERABLE 6

Draft Sickle Cell Disease Study Report

SUPPORTING DOCUMENTATION

The Vendor shall submit a draft sickle cell disease study report that in accordance with Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub- Section B. Services Provided by the Vendor, Item 1.b.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

DocuSign Envelope ID: 74365CBA-125F-4341-8681-486861B1C254DocuSign Envelope ID: 28B79FAF-8443-4D94-8A6D-88A66FE263AB

REVISED DELIVERABLES, FINANCIAL CONSEQUENCES AND PERFORMANCE

STANDARDS

AHCA Contract No. MED216, Exhibit A-1, Page 4 of 12

November 1, 2022, or as otherwise approved by the Agency. (COMPLETED)

AMOUNT

$118,222.20

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub- Section B., Services Provided by the Vendor, Item 1.b.

FINANCIAL CONSEQUENCES

Failure to complete and submit Deliverable 1 in the time and manner specified in accordance with this Contract will result in a payment reduction equal to ten percent (10%) of the total invoiced amount.

7.

DELIVERABLE 7

Final Draft Sickle Cell Disease Study Report

SUPPORTING DOCUMENTATION

The Vendor shall submit a draft sickle cell disease study report in accordance with Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub- Section B. Services Provided by the Vendor, Item 1.b.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

December 1, 2022, or as otherwise approved by the Agency. (COMPLETED)

AMOUNT

$78,814.80

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub- Section B., Services Provided by the Vendor, Item 1.b.

FINANCIAL CONSEQUENCES

Failure to complete and submit Deliverable 2 in the time and manner specified in accordance with this Contract will result in a payment reduction equal to ten percent (10%) of the total invoiced amount.

8.

DELIVERABLE 8

Criteria for Florida Centers of Excellence for Sickle Cell Disease

SUPPORTING DOCUMENTATION

The Vendor will submit a summary in accordance with Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B. Services Provided by the Vendor, Item 1.c.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

2/10/2023 (COMPLETED)

DocuSign Envelope ID: 74365CBA-125F-4341-8681-486861B1C254DocuSign Envelope ID: 28B79FAF-8443-4D94-8A6D-88A66FE263AB

REVISED DELIVERABLES, FINANCIAL CONSEQUENCES AND PERFORMANCE

STANDARDS

AHCA Contract No. MED216, Exhibit A-1, Page 5 of 12

AMOUNT

$9,755.00

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub- Section B., Services Provided by the Vendor, Item 1.c.

FINANCIAL CONSEQUENCES

Failure to complete and submit Deliverable 8 in the time and manner specified in accordance with this Contract will result in a payment reduction equal to ten percent (10%) of the total invoiced amount.

9.

DELIVERABLE 9

Provider Education on Treating Patients with Sickle Cell Disease

SUPPORTING DOCUMENTATION

The Vendor will submit a summary in accordance with Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B. Services Provided by the Vendor, Item 1.d.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

4/28/2023 (COMPLETED)

AMOUNT

$10,000.00

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub- Section B., Services Provided by the Vendor, Item 1.d.

FINANCIAL CONSEQUENCES

Failure to complete and submit Deliverable 9 in the time and manner specified in accordance with this Contract will result in a payment reduction equal to 10 percent of the total invoiced amount.

10.

DELIVERABLE 10

Preferred Drug List for Treating Patients with Sickle Cell Disease

SUPPORTING DOCUMENTATION

The Vendor will submit a summary in accordance with Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B. Services Provided by the Vendor, Item 1.e.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

DocuSign Envelope ID: 74365CBA-125F-4341-8681-486861B1C254DocuSign Envelope ID: 28B79FAF-8443-4D94-8A6D-88A66FE263AB

REVISED DELIVERABLES, FINANCIAL CONSEQUENCES AND PERFORMANCE

STANDARDS

AHCA Contract No. MED216, Exhibit A-1, Page 6 of 12

11.

DELIVERABLE 11

Performance Measures for Treating Patients with Sickle Cell Disease

SUPPORTING DOCUMENTATION

The Vendor will submit a summary in accordance with Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B. Services Provided by the Vendor, Item 1.f.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

4/21/2023 (COMPLETED)

AMOUNT

$8,000.00

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub- Section B., Services Provided by the Vendor, Item 1.f.

FINANCIAL CONSEQUENCES

Failure to complete and submit Deliverable 11 in the time and manner specified in accordance with this Contract will result in a payment reduction equal to 10 percent of the total invoiced amount.

3/31/2023 (COMPLETED)

AMOUNT

$20,000.00

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub- Section B., Services Provided by the Vendor, Item 1.e.

FINANCIAL CONSEQUENCES

Failure to complete and submit Deliverable 10 in the time and manner specified in accordance with this Contract will result in a payment reduction equal to 10 percent of the total invoiced amount.

12.

DELIVERABLE 12

External Funding Opportunities for a Florida Consortium of Centers of Excellence in Sickle Cell Disease

SUPPORTING DOCUMENTATION

The Vendor will submit a summary in accordance with Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B. Services Provided by the Vendor, Item 1.g.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one

DocuSign Envelope ID: 74365CBA-125F-4341-8681-486861B1C254DocuSign Envelope ID: 28B79FAF-8443-4D94-8A6D-88A66FE263AB

REVISED DELIVERABLES, FINANCIAL CONSEQUENCES AND PERFORMANCE

STANDARDS

AHCA Contract No. MED216, Exhibit A-1, Page 7 of 12

13.

DELIVERABLE 13

Sickle Cell Disease (SCD) Report Outline

SUPPORTING DOCUMENTATION

The Vendor shall develop and submit a Sickle Cell Disease Report outline.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

February 1, 2024

AMOUNT

$20,000.00

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub- Section B., Services Provided by the Vendor, Item 1.c.

FINANCIAL CONSEQUENCES

Failure to complete and submit the deliverables that meet the minimum quality standards in the time and manner specified in accordance with this Contract will result in a payment reduction equal to ten percent (10%) of the total invoiced amount.

hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

5/19/2023 (COMPLETED)

AMOUNT

$5,208.00

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub- Section B., Services Provided by the Vendor, Item 1.g.

FINANCIAL CONSEQUENCES

Failure to complete and submit Deliverable 12 in the time and manner specified in accordance with this Contract will result in a payment reduction equal to 10 percent of the total invoiced amount.

14.

DELIVERABLE 14

Draft Sickle Cell Disease (SCD) Study Report

SUPPORTING DOCUMENTATION

The Vendor shall develop and submit a Sickle Cell Disease Draft Report in accordance with Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub- Section B. Services Provided by the Vendor, Item 1.d, and shall include, at a minimum, the following component: the purpose of the report, an executive summary; consultations;

background fundamentals of sickle cell disease; findings, including the total number of Medicaid recipients diagnosed with Sickle Cell Disease, age and population demographics of people with SCD, health care utilization patterns of Florida Medicaid

DocuSign Envelope ID: 74365CBA-125F-4341-8681-486861B1C254DocuSign Envelope ID: 28B79FAF-8443-4D94-8A6D-88A66FE263AB

REVISED DELIVERABLES, FINANCIAL CONSEQUENCES AND PERFORMANCE

STANDARDS

AHCA Contract No. MED216, Exhibit A-1, Page 8 of 12 recipients with SCD, expenditures for Florida Medicaid recipients with SCD, high-utilizers of healthcare services, and clinical treatment programs; and appendix including, methods, pharmaceutical utilization and expenditures, expenditures for medical services in high-utilizers and low utilizers with SCD, and expenditures of pharmaceutical services in low versus high utilizer populations.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

May 30, 2024

AMOUNT

$200,000.00

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub- Section B., Services Provided by the Vendor, Item 1. d.

FINANCIAL CONSEQUENCES

Failure to complete and submit the deliverables that meet the minimum quality standards in the time and manner specified in accordance with this Contract will result in a payment reduction equal to 10 percent of the total invoiced amount.

15.

DELIVERABLE 15

Final Draft Sickle Cell Disease (SCD) Study Report

SUPPORTING DOCUMENTATION

The Vendor shall develop and submit a Sickle Cell Disease Final Report in accordance with Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub- Section B. Services Provided by the Vendor, Item 1.d, and shall include, at a minimum, the following components: the purpose of the report, an executive summary;

consultations; background fundamentals of sickle cell disease; findings, including the total number of Medicaid recipients diagnosed with Sickle Cell Disease, age and population demographics of people with SCD, health care utilization patterns of Florida Medicaid recipients with SCD, expenditures for Florida Medicaid recipients with SCD, high-utilizers of healthcare services, and clinical treatment programs; and appendix including, methods, pharmaceutical utilization and expenditures, expenditures for medical services in high-utilizers and low utilizers with SCD, and expenditures of pharmaceutical services in low versus high utilizer populations.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

June 30, 2024

AMOUNT

$30,000.00

PERFORMANCE STANDARDS

DocuSign Envelope ID: 74365CBA-125F-4341-8681-486861B1C254DocuSign Envelope ID: 28B79FAF-8443-4D94-8A6D-88A66FE263AB

REVISED DELIVERABLES, FINANCIAL CONSEQUENCES AND PERFORMANCE

STANDARDS

AHCA Contract No. MED216, Exhibit A-1, Page 9 of 12

1. Additional Deliverable Requirements:

a) The Vendor shall submit deliverables electronically, in draft form, using Microsoft Word or a comparable word processing application to the Agency’s Contract Manager for review. Each deliverable shall be considered and labeled “draft” via the electronic file name and within the document name until the Agency has reviewed and approved the deliverable in writing. Draft deliverables should require minimal revisions as specified in the quality standards requirements below (in this Section, item e). Each deliverable must have a cover sheet with the project deliverable number, deliverable name, Vendor’s name, and date (month/year).

b) At a minimum, the Agency’s review process will include:

(1) An initial review by the Agency’s Contract Manager to ensure that the deliverable meets minimum quality standards;

(2) Review by internal Agency staff, including the Agency’s Chief Medical Officer, program, policy, and research staff; and

(3) Final review and sign off by the appropriate Agency management staff, per deliverable, at the sole discretion of the Agency.

c) For purposes of this Contract, the following elements shall be present in each deliverable submitted to the Agency for review in order to meet the Agency’s minimum quality standards:

(1) The deliverable is complete (all sections contain adequate information for an effective review);

(2) The deliverable is accurately and consistently labeled in accordance with the Contract deliverable number, name and edition (i.e., draft or final);

(3) Deliverables shall be written for the non-researcher stakeholder and submitted in the current American Psychological Association (APA) format, including for all citations, notes and references (if applicable);

(4) The deliverable reflects a logical flow of information and/or ideas;

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub- Section B., Services Provided by the Vendor, Item 1.e.

FINANCIAL CONSEQUENCES

Failure to complete and submit the deliverables that meet the minimum quality standards in the time and manner specified in accordance with this Contract will result in a payment reduction equal to 10 percent of the total invoiced amount.

DocuSign Envelope ID: 74365CBA-125F-4341-8681-486861B1C254DocuSign Envelope ID: 28B79FAF-8443-4D94-8A6D-88A66FE263AB

REVISED DELIVERABLES, FINANCIAL CONSEQUENCES AND PERFORMANCE

STANDARDS

AHCA Contract No. MED216, Exhibit A-1, Page 10 of 12

(5) The deliverable contains current and relevant references with consistent, appropriate grammar and referencing style;

(6) The deliverable uses proper terminology;

(7) The deliverable contains unbiased and comprehensive synthesis of the research results;

(8) The deliverable displays accurate presentation of the data elements and analysis that is supported by the data presented;

(9) The deliverable has minimal grammatical, stylistic and spelling errors (less than an average of three (3) per page); and

(10) The deliverable reflects adherence to the Agency approved project-specific proposal.

d) Deliverables that do not meet the minimum standards described above will be deemed out-of-compliance, subject to financial consequences and returned to the Contract Manager, as defined in Section II., Manner of Service(s) Provision, Sub- Section E., Staffing, within five (5) business days of Agency review and will not be forwarded to internal Agency reviewers until the deliverable is revised and meets minimum quality standards. The Vendor shall have three (3) business days from the date that specific out-of-compliance items are identified in writing by the Agency Contract Manager to submit a revised deliverable that meets the minimum deliverable and quality standards. Business days are hereby defined as Monday through Friday, excluding State of Florida observed holidays.

e) Deliverables that are submitted late or that do not meet the minimum quality standards established above and that require resubmission will be reviewed as soon as Agency staff are able to review. Any subsequent deliverable due dates that are affected because a previous deliverable did not meet minimum quality standards or was submitted late are the responsibility of the Vendor and may incur financial consequences associated with the late submission.

f) Deliverables that meet the deliverable requirements and minimum quality standards may still require revision based on Agency review, comments and questions. If the Agency determines revisions are needed, the Agency will notify the Vendor, in writing, within fourteen (14) calendar days of receipt of the draft deliverable. The Agency shall provide the Vendor, in writing, all requested revisions, comments or questions relating to the deliverable. The Vendor shall respond in writing to questions, comments and suggested deliverable edits/revisions within seven (7) calendar days of receipt unless otherwise directed by the Agency. If the Agency determines additional revision(s) are needed, the Agency will notify the Vendor in writing, within five (5) calendar days of receipt of

DocuSign Envelope ID: 74365CBA-125F-4341-8681-486861B1C254DocuSign Envelope ID: 28B79FAF-8443-4D94-8A6D-88A66FE263AB

REVISED DELIVERABLES, FINANCIAL CONSEQUENCES AND PERFORMANCE

STANDARDS

AHCA Contract No. MED216, Exhibit A-1, Page 11 of 12 the revised draft deliverable. Written notification will include all requested revisions, comments or questions relating to the revised draft deliverable, the date the revisions and written responses to comments or questions are due (minimum of three (3) calendar days) and the revised final due date if applicable. The Agency reserves the right to adjust review times as necessary.

g) Once the Agency has reviewed and approved the “draft” deliverable in writing, the Vendor shall submit a deliverable labeled “Final” electronically. Deliverables that include Personal Health Information shall be encrypted and require a redacted version to be submitted in addition to the encrypted version.

h) Deliverables that are late due to the Vendor’s failure to adequately address the Agency’s requested changes are subject to financial consequences.

i) The Vendor shall submit requests for extensions for deliverables, in writing, to the Agency’s Contract Manager for approval at least fourteen (14) calendar days prior to the established due date. At a minimum, requests for extension shall include the following:

(1) The reason for the request;

(2) The proposed alternative due date; and

(3) Any impact the extension will have on any other deliverable.

The Agency shall provide written response to the Vendor’s request within seven

(7) calendar days. It is at the Agency’s sole discretion whether a request for extension is approved. The original due date will remain in effect until a revised due date has been approved by formal Amendment to this Contract.

j) The Vendor will not be held responsible for missed deliverable due dates that are due solely to Agency review that exceeds fourteen (14) calendar days or delays in obtaining data and information that were properly and timely requested from the Agency, provided the Vendor notifies the Agency that the deliverables will be late prior to the due date. If the Vendor determines that the due dates cannot be met due to excessive Agency review time or delays in obtaining data or information, they must notify the Agency in writing at least seven (7) calendar days prior to the established due date that the deliverable(s) will be late. Such notification shall follow the format outlined in paragraph (k) above in all respects except the required notification is only seven (7) calendar days.

The Vendor will not be penalized for deliverables that are late due to delays in the Agency review process or delays in obtaining properly requested data, provided the number of days past the due date does not exceed the delays attributable solely to the Agency. If approved, the due dates will be changed by formal

DocuSign Envelope ID: 74365CBA-125F-4341-8681-486861B1C254DocuSign Envelope ID: 28B79FAF-8443-4D94-8A6D-88A66FE263AB

REVISED DELIVERABLES, FINANCIAL CONSEQUENCES AND PERFORMANCE

STANDARDS

AHCA Contract No. MED216, Exhibit A-1, Page 12 of 12

Amendment to this Contract to reflect the additional time attributable to delays at the Agency.

DocuSign Envelope ID: 74365CBA-125F-4341-8681-486861B1C254DocuSign Envelope ID: 28B79FAF-8443-4D94-8A6D-88A66FE263AB